CVM Stock Summary and Trading Ideas (Cel-Sci | AMEX:CVM)

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Cel-Sci trades on the AMEX stock market under the symbol CVM.

As of October 30, 2026, CVM stock price declined to $1.38 with 187,653 million shares trading.

CVM has a beta of 2.57, meaning it tends to be more sensitive to market movements. CVM has a correlation of 0.08 to the broad based SPY ETF.

CVM has a market cap of $24.27 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CVM traded as high as $96.90 and as low as $.89.

The top ETF exchange traded funds that CVM belongs to (by Net Assets): VTI, VXF, BUSM.

CVM has underperformed the market in the last year with a price return of -81.8% while the SPY ETF gained +11.0%. However, in the short term, CVM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.1% vs +3.9% return in SPY. But in the last 2 weeks, CVM shares have been beat by the market, returning -20.7% compared to an SPY return of -2.1%.

CVM support price is $1.38 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVM shares will trade within this expected range on the day.